Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia

NCT01146522 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperlipoproteinemia

Interventions

DRUG: LCQ908
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals